ITGB3 and pulmonary arterial hypertension: These data suggested that miR‐223‐3p and ITGB3 are involved in PAH, and these results uncovered for the first time that miR‐223‐3p inhibits PAH by targeting ITGB3. These findings may provide a new therapeutic target for the treatment of PAH.